AMPER Proof of Concept Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorUniversity of Strathclyde

About this trial

The AMPER (Agent-based Memory Prosthesis to Encourage Reminiscing) system has been built to help people with Alzheimer's disease by improving their memory recall and quality of life. Alzheimer's often leads to the loss of autobiographical memories, which can affect a person's sense of identity. AMPER seeks to address this by creating a digital memory aid that uses an engaging, animated character on a tablet to help individuals with Alzheimer's reminisce about their past. By presenting personally relevant stories, images, audio, and videos, the character helps trigger memories and encourages interaction with caregivers.

This is proof of concept study using a randomised controlled trial methodology. Twenty participants will be randomised to the control and 20 randomised to the intervention condition. The intervention group will use a personalised version of the AMPER app with tailored content and the control group will use a non-personalised version without specific adaptations. Over 12 weeks, participants will use the app at home with their caregivers. Researchers will measure changes in their memory and cognitive abilities before and after these 12 weeks.

The primary goal is to see if personalised reminiscence improves the perceived quality of the reminiscence experience and autobiographical memory ability compared to the same app with a non-personalised approach. This will be measured using a combination of automatically gathered app use data and weekly caregiver feedback. Secondary goals are to investigate any difference between participants in the intervention and control condition in their technology acceptance, quality of life, self-esteem, everyday functioning and cognitive ability.

Feedback from this research will help refine AMPER and inform future studies, with the ultimate goal of creating a widely accessible tool that supports memory and well-being in Alzheimer's patients. Table 1 provides a summary of the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 50 or older

Sensory (visual and auditory), language, and physical abilities adequate to perform assessments (corrective aids allowed).

ACE III score between 20 and 82 (inclusive) (or equivalent score on MMSE (between 14 and 24, based on Law et al., 20123 equivalence data) or MOCHA (between 14 and 24 (based on Pendleberry et al., 2011 equivalence data).

Having a caregiver or family member who can attend all visits, perform assessments, and supervise administration of study.

Disqualifiers

Medical records indicate AD patients with the visual variant or having colour vision deficits.

Medical records indicate a CT or MRI within 24 months prior to screening that indicates a diagnosis other than probable Alzheimer's disease.

Medical records indicate any significant neurological disease other than probable AD (e.g. Parkinson's disease, Huntington's disease, brain tumor, normal pressure hydrocephalus, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of stroke, or history of head injury requiring hospitalization).

On review of medical records, no clinically significant abnormal findings on previous physical examination, medical history, or clinical laboratory results that would indicate an alternative diagnosis.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)

    Device

    AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Personalised AMPER is personalised to preferences and age of the participant.

  • Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)

    Device

    AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Non-personliased AMPER is not personalised to preferences or age of the participant.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Personalised AMPERExperimental treatment 1 intervention
Group B: Non-personalised AMPERActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Quality of autobiographical memory during AMPER use

We will analyse the richness of episodic and semantic details in the participant's recollections (which are audio recorded during the trial). This method will ensure a systematic evaluation of memory quality during interactions facilitated by the AMPER app. This rating procedure will use the methodology outlined by Levine and colleagues (2002) and will be scored using the semi-automated methodology outlined by Wardell and colleagues (2021).

Time frame
From enrollment to the end of AMPER use at 12 weeks
2

Autobiographical Memory ability (objectively rated)

Objective rating of Autobiographical Memory ability using the Autobiographical Memory Interview (Kopelman et al., 1989)

Time frame
Baseline (week 1) and follow up (week 14)
3

Autobiographical Memory ability (subjectively rated)

Autobiographical memory ability will be subjectively rated using the Autobiographical Recollection Test (ART), (Berntsen et al., 2019).

Time frame
Baseline (week 1) and follow up (week 14)
4

Autobiographical Memory ability (subjectively rated on SAM)

Autobiographical memory ability will also be subjectively rated using the survey of Autobiographical memory (SAM), (Palombo et al., 2012)

Time frame
Baseline (week 1) and follow up (week 14)

Secondary outcomes

1

Functional ability in tasks of everyday living

Instrumental Activities of Daily Living (IADL), (Lawton \& Brody, 1969)

Time frame
Baseline (week 1) and follow up (week 14)
2

Quality of life for the individual with Alzheimer's disease (subjective)

Quality of life Alzheimer's Disease (Logsdon et al., 1999)

Time frame
Baseline (week 1) and follow up (week 14)
3

Level of Depression experienced by the person with AD (subjective)

Geriatric Depression Scale (GDS), (Yesavage et al., 1982),

Time frame
Baseline (week 1) and follow up (week 14)
4

Cognitive ability of the person with AD

Addenbrooke's Cognitive Examination ACE-III (Mioshi et al., 2006)

Time frame
Baseline (week 1) and follow up (week 14)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Strathclyde

Lead sponsor

NHS Greater Glasgow and Clyde

Collaborator

This trial is not recruiting at the moment. You can still explore other options: